Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis

被引:71
作者
Kaufman, Gregory P. [1 ]
Dispenzieri, Angela [1 ,2 ]
Gertz, Morie A. [1 ,2 ]
Lacy, Martha Q. [1 ,2 ]
Buadi, Francis K. [1 ,2 ]
Hayman, Suzanne R. [1 ,2 ]
Leung, Nelson [1 ,2 ,3 ]
Dingli, David [1 ,2 ]
Lust, John A. [1 ,2 ]
Lin, Yi [1 ,2 ]
Kapoor, Prashant [1 ,2 ]
Go, Ronald S. [1 ,2 ]
Zeldenrust, Steven R. [1 ,2 ]
Kyle, Robert A. [1 ,2 ]
Rajkumar, S. Vincent [1 ,2 ]
Kumar, Shaji K. [1 ,2 ]
机构
[1] Mayo Clin, Dept Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
[3] Mayo Clin, Div Nephrol, Rochester, MN 55905 USA
关键词
STEM-CELL TRANSPLANTATION; HIGH-DOSE MELPHALAN; PRIMARY SYSTEMIC AMYLOIDOSIS; NATRIURETIC PEPTIDE; DEXAMETHASONE; COMBINATION; INVOLVEMENT; IMPROVEMENT; BORTEZOMIB;
D O I
10.1002/ajh.23898
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite successful treatment of the clonal plasma cell implicated in its pathogenesis, patients with AL amyloidosis (AL) experience significant morbidity related to underlying amyloid mediated organ dysfunction. While normalization of the serum free light chain measurements [normal ratio of involved and uninvolved free light chains (nFLCr)] is the goal of therapy and centerpiece of hematologic response criteria, achieving (or not achieving) meaningful organ response (OR) is clinically significant for its implications on long-term symptomatology as well as overall survival (OS), and remains the ultimate goal of treatment. Expectations for organ recovery following successful therapy leading to nFLCr in AL remain poorly described. We evaluated the timeframe and predictive factors for OR, and long-term outcome, in 313 AL patients who achieved nFLCr following therapy initiation. OR was seen in 80% of surviving AL patients within 1-year of nFLCr. Patients achieving early OR within 1 year of nFLCr had superior OS compared with those who despite obtaining nFLCr did not achieve early OR. We further evaluated factors predicting OR and OS among patients achieving nFLCr. Higher values of dFLC (involved-uninvolved) at diagnosis predict OR, and early OR predicts improved OS following successful hematologic therapy in AL. Am. J. Hematol. 90:181-186, 2015. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:181 / 186
页数:6
相关论文
共 26 条
  • [1] Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)
    Bochtler, Tilmann
    Hegenbart, Ute
    Heiss, Christiane
    Benner, Axel
    Moos, Marion
    Seckinger, Anja
    Pschowski-Zuck, Stephanie
    Kirn, Desiree
    Neben, Kai
    Bartram, Claus R.
    Ho, Anthony D.
    Goldschmidt, Hartmut
    Hose, Dirk
    Jauch, Anna
    Schonland, Stefan O.
    [J]. BLOOD, 2011, 117 (14) : 3809 - 3815
  • [2] Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease
    Dember, LM
    Sanchorawala, V
    Seldin, DC
    Wright, DG
    LaValley, M
    Berk, JL
    Falk, RH
    Skinner, M
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 134 (09) : 746 - 753
  • [3] Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Dispenzieri, A
    Lacy, MQ
    Katzmann, JA
    Rajkumar, SV
    Abraham, RS
    Hayman, SR
    Kumar, SK
    Clark, R
    Kyle, RA
    Litzow, MR
    Inwards, DJ
    Ansell, SM
    Micallef, IM
    Porrata, LF
    Elliott, MA
    Johnston, PB
    Greipp, PR
    Witzig, TE
    Zeldenrust, SR
    Russell, SJ
    Gastineau, D
    Gertz, MA
    [J]. BLOOD, 2006, 107 (08) : 3378 - 3383
  • [4] Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival
    Dispenzieri, A
    Lacy, MQ
    Kyle, RA
    Therneau, TM
    Larson, DR
    Rajkumar, SV
    Fonseca, R
    Greipp, PR
    Witzig, TE
    Lust, JA
    Gertz, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) : 3350 - 3356
  • [5] Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
    Dispenzieri, A
    Gertz, MA
    Kyle, RA
    Lacy, MQ
    Burritt, MF
    Therneau, TM
    Greipp, PR
    Witzig, TE
    Lust, JA
    Rajkumar, SV
    Fonseca, R
    Zeldenrust, SR
    McGregor, CGA
    Jaffe, AS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) : 3751 - 3757
  • [6] Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy
    Gertz, MA
    Lacy, MQ
    Dispenzieri, A
    Greipp, PR
    Litzow, MR
    Henderson, KJ
    Van Wier, SA
    Ahmann, GJ
    Fonseca, R
    [J]. BLOOD, 2005, 106 (08) : 2837 - 2840
  • [7] Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
    Gertz, MA
    Comenzo, R
    Falk, RH
    Fermand, JP
    Hazenberg, BP
    Hawkins, PN
    Merlini, G
    Moreau, P
    Ronco, P
    Sanchorawala, V
    Sezer, O
    Solomon, A
    Grateau, G
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2005, 79 (04) : 319 - 328
  • [8] GERTZ MA, 1991, BLOOD, V77, P257
  • [9] Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management
    Gertz, Morie A.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (02) : 181 - 186
  • [10] Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney
    Gertz, Morie A.
    Leung, Nelson
    Lacy, Martha Q.
    Dispenzieri, Angela
    Zeldenrust, Steven R.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dingli, David
    Greipp, Philip R.
    Kumar, Shaji K.
    Lust, John A.
    Rajkumar, S. Vincent
    Russell, Stephen J.
    Witzig, Thomas E.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (10) : 3132 - 3137